DWA
IMNM icon

Dorsey Wright & Associates’s Immunome IMNM Stock Holding History

Dorsey Wright & Associates’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,100
Closed -$25.9K – 207
2023
Q3 		$25.9K Buy
+3,100
New +$22.8K 0.01% 200

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dorsey Wright & Associates's IMNM Position: Q4 2023 in Review

Dorsey Wright & Associates sold out of Immunome (IMNM) in Q4 2023, closing a stake of 3,100 shares — an estimated $25.9K sold.

Dorsey Wright & Associates first reported a position in IMNM in Q3 2023 and held it in 1 quarter. The position peaked at $25.9K in Q3 2023. 57 funds tracked by Wall St. Rank hold IMNM as of Q4 2023.

  • Dorsey Wright & Associates reported no remaining Immunome position as of Q4 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 3,100 Immunome shares in Q4 2023, an estimated $25.9K.
  • Dorsey Wright & Associates first reported a position in Immunome in Q3 2023 and held it in 1 quarter.
  • Dorsey Wright & Associates's Immunome position peaked at $25.9K in Q3 2023.
  • 57 funds tracked by Wall St. Rank held Immunome as of Q4 2023.

Based on Dorsey Wright & Associates's 13F filing for Q4 2023, filed 13 Feb 2024.